drugset / Trial / NCT07132112
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Phase 0
Recruiting
30 enrolled
Grit Biotechnology
Affiliated Hospital of Nantong University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.
Timeline
- Start
- 2025-10-28
- Primary completion
- 2028-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT719 | Cell therapy | — | — |